← Twist Bioscience Corp
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | — | $10.8m |
$25.4m
+136.16%
|
$54.4m
+113.89%
|
$90.1m
+65.67%
|
$132.3m
+46.87%
|
$203.6m
+53.83%
|
$245.1m
+20.41%
|
$313.0m
+27.69%
|
$376.6m
+20.32%
|
$431.8m
+14.67%
|
|
| Cost of Goods and Services Sold | — | $24.0m |
$32.2m
+34.01%
|
$47.4m
+47.34%
|
$61.4m
+29.48%
|
$80.6m
+31.29%
|
$119.3m
+48.02%
|
$155.4m
+30.21%
|
$179.6m
+15.60%
|
$185.6m
+3.31%
|
$207.4m
+11.77%
|
|
| Cost of revenues | — | $24.0m |
$32.2m
+34.01%
|
$47.4m
+47.34%
|
$61.4m
+29.48%
|
$80.6m
+31.29%
|
$119.3m
+48.02%
|
$155.4m
+30.21%
|
$179.6m
+15.60%
|
$185.6m
+3.31%
|
$207.4m
+11.77%
|
|
| Gross Profit | — | ($13.3m) |
($6.8m)
+48.98%
|
$7.0m
+202.91%
|
$28.7m
+312.33%
|
$51.7m
+80.22%
|
$84.2m
+62.89%
|
$89.7m
+6.52%
|
$133.3m
+48.61%
|
$191.0m
+43.23%
|
$224.4m
+17.48%
|
|
| Research And Development | — | $19.2m | $20.3m | $35.7m | $43.0m | $69.1m | $120.3m | $106.9m | $90.9m | $80.3m | $71.9m | |
| Amortization of Intangible Assets | — | — | — | — | — | — | $4.9m | $5.3m | $4.1m | $1.1m | — | |
| Restructuring And Mergern Acquisition | — | — | — | — | — | — | ($14.2m) | $3.5m | $0 | $0 | $0 | |
| Operating Lease, Expense | — | — | — | — | $7.9m | $9.5m | $15.6m | $16.2m | — | — | — | |
| Restructuring Costs | — | — | — | — | — | — | — | $16.2m | $0 | $0 | — | |
| Restructuring and other costs | — | — | — | — | — | $0 | $0 | $16.2m | $0 | $0 | — | |
| Operating expenses: | ||||||||||||
| Loss from operations | — | ($58.5m) |
($70.6m)
-20.65%
|
($108.8m)
-54.27%
|
($140.1m)
-28.69%
|
($152.7m)
-9.03%
|
($234.8m)
-53.72%
|
($217.2m)
+7.50%
|
($220.8m)
-1.69%
|
($136.3m)
+38.30%
|
— | |
| Other Non Operating Income Expenses | — | — | — | — | — | — | ($1.1m) | ($672k) | ($2.7m) | ($903k) | — | |
| Operating Income (Loss) | — | ($58.5m) |
($70.6m)
-20.65%
|
($108.8m)
-54.27%
|
($140.1m)
-28.69%
|
($152.7m)
-9.03%
|
($234.8m)
-53.72%
|
($217.2m)
+7.50%
|
($220.8m)
-1.69%
|
($136.3m)
+38.30%
|
($137.8m)
-1.11%
|
|
| Interest Income, Operating | — | — | — | — | — | — | — | — | — | $0 | $8.0m | |
| Interest income | — | $412k | $999k | $3.0m | $1.5m | $435k | $3.1m | $14.4m | $15.3m | $11.4m | $8.0m | |
| Gain on sale of business | — | — | — | — | — | — | $4.6m | $0 | $0 | $48.8m | $0 | |
| Change in unrealized gain (loss) on investments | — | ($9k) | — | $49k | ($34k) | ($14k) | ($1.6m) | $1.5m | $203k | ($50k) | — | |
| Other Nonoperating Income (Expense) | — | ($55k) | ($121k) | ($265k) | ($182k) | ($1.4m) | ($1.1m) | ($667k) | ($2.6m) | ($903k) | — | |
| Other income (expense), net | — | ($55k) | ($121k) | ($265k) | ($182k) | ($1.4m) | ($1.1m) | ($667k) | ($2.6m) | ($903k) | ($6.1m) | |
| Interest Expense (non-operating) | — | — | — | $1.3m | $787k | $367k | $80k | $5k | $29k | — | $195k | |
| Other Income Expense | — | — | — | — | — | — | $17.8m | ($10.9m) | ($47.6m) | $47.9m | ($6.1m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | — | — | ($149.5m) | ($231.7m) | ($205.4m) | ($209.5m) | ($78.5m) | ($135.9m) | |
| Loss before income taxes | — | ($59.0m) | ($71.0m) | ($107.4m) | ($139.5m) | ($154.0m) | ($228.3m) | ($203.5m) | ($208.2m) | ($77.0m) | — | |
| Pre-Tax Income | — | ($59.0m) | ($71.0m) | ($107.4m) | ($139.5m) | ($154.0m) | ($228.3m) | ($203.5m) | ($208.2m) | ($77.0m) | ($135.9m) | |
| Current Income Tax Expense (Benefit) | — | — | — | — | — | $79k | $766k | $1.2m | $560k | $719k | $864k | |
| Income tax expense | — | ($280k) | ($242k) | ($292k) | ($382k) | $1.9m | $10.4m | ($1.2m) | ($560k) | ($719k) | $864k | |
| Net Income From Continuing And Discontinued Operation | — | ($59.3m) | ($71.2m) | ($107.7m) | ($139.9m) | ($152.1m) | ($217.9m) | ($204.6m) | ($208.7m) | ($77.7m) | ($136.7m) | |
| Net loss attributable to common stockholders | — | ($59.3m) | ($71.2m) | ($107.7m) | ($139.9m) | ($152.1m) | ($217.9m) | ($204.6m) | ($208.7m) | ($77.7m) | — | |
| Earnings Per Share, Basic | — | — | — | — | — | ($3.15) | ($4.04) | ($3.60) | ($3.60) | ($1.30) | ($2.23) | |
| Earnings Per Share, Diluted | — | — | — | — | — | ($3.15) | ($4.04) | ($3.60) | ($3.60) | ($1.30) | ($2.23) | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | — | — | 53.9m | 56.9m | 58.0m | 59.8m | 61.1m | |
| Basic Average Shares | — | — | — | — | — | — | $53.9m | $56.9m | $58.0m | $59.8m | $61.1m | |
| Diluted Average Shares | — | — | — | — | — | — | $53.9m | $56.9m | $58.0m | $59.8m | $61.1m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | — | — | 53.9m | 56.9m | 58.0m | 59.8m | 61.1m | |
| Additional Financial Items | ||||||||||||
| Capitalized Computer Software, Amortization | — | — | — | — | — | — | — | — | $2.6m | $2.9m | — | |
| Depreciation, Depletion and Amortization, Nonproduction | — | — | — | $6.1m | — | — | — | — | — | — | — | |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount | — | — | — | — | — | — | — | — | — | $1.1m | — | |
| Realized Investment Gains (Losses) | — | — | — | — | — | $5k | $0 | — | — | — | — | |
| Change in fair value of contingent considerations and holdbacks | — | — | — | — | $0 | ($534k) | ($14.2m) | ($5.9m) | $0 | $0 | — | |
| Impairment of long-lived assets | — | — | — | — | — | — | $0 | $6.8m | $44.9m | $0 | — | |
| Foreign currency translation adjustment | — | $33k | $54k | $45k | ($60k) | $473k | ($795k) | ($423k) | $31k | ($55k) | — | |
| Comprehensive loss | — | ($59.3m) | ($71.2m) | ($107.6m) | ($140.0m) | ($151.6m) | ($220.3m) | ($203.5m) | ($208.5m) | ($77.8m) | — | |
| Diluted EPS | — | — | — | — | — | ($3.15) | ($4.04) | ($3.60) | ($3.60) | ($1.30) | ($2.23) | |
| Diluted NI Availto Com Stockholders | — | ($59.3m) | ($71.2m) | ($107.7m) | ($139.9m) | ($152.1m) | ($217.9m) | ($204.6m) | ($208.7m) | ($77.7m) | ($136.7m) | |
| Impairment Of Capital Assets | — | — | — | — | — | — | $0 | $6.8m | $44.9m | $0 | $0 | |
| Normalized EBITDA | — | — | — | — | — | — | ($230.5m) | ($167.3m) | ($99.5m) | ($160.3m) | ($112.4m) | |
| Normalized Income | — | — | — | — | — | — | ($235.8m) | ($196.5m) | ($163.8m) | ($116.3m) | ($132.4m) | |
| Reconciled Depreciation | — | — | — | — | — | — | $16.5m | $29.3m | $31.4m | $24.9m | $25.4m | |
| Selling General And Administration | — | $26.1m | $43.5m | $80.1m | $103.3m | $135.9m | $212.9m | $189.7m | $218.4m | $247.0m | — | |
| Special Income Charges | — | — | — | — | — | — | $18.9m | ($10.3m) | ($44.9m) | $48.8m | ($7.2m) | |
| Tax Effect Of Unusual Items | — | — | — | — | — | — | $943k | ($2.2m) | $0 | $10.3m | ($2.9m) | |
| Tax Provision | — | — | — | — | — | — | ($10.4m) | $1.2m | $560k | $719k | $864k | |
| Tax Rate For Calcs | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | |
| Costs and Expenses | — | $69.2m | $96.0m | $163.2m | $230.2m | $285.1m | $438.3m | $462.3m | $533.8m | $512.8m | — | |
| Operating Expense | — | — | — | — | — | — | $333.3m | $296.6m | $309.2m | $327.3m | $362.2m | |
| Total Unusual Items | — | — | — | — | — | — | $18.9m | ($10.3m) | ($44.9m) | $48.8m | ($7.2m) | |
| Total Expenses | — | — | — | — | — | — | $452.6m | $452.0m | $488.9m | $512.8m | $569.6m |